ARCHIVES

IVAX Agreement With Rival BMS Appears To Buttress BMS control of Paclitaxel

This article is from The Cancer Letter archive.

Vol. 25 No. 45 | November 26, 1999

Download PDF Visit The Full Archive

Related Articles

VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial

May 30, 2014

NCI’s SBIR Awards Move Up In Quality; Congress considers Making It Permanent; FASEB Object

September 19, 1986

In Brief: Senate Subcommittee Recommends $1 .52 Billion

September 25, 1987

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

July 26, 2013

NCI Staff Suggest New Community Oncology, Pain Control, Nurse, Pathology Center Projects

May 13, 1977

ORI Progress On Fisher Case Questioned; Panel Not Formed

March 3, 1995